Palatin Technologies (PTN)

$0.09 -0.08 (-44.65%)
Market Cap 2.45M
Revenue (ttm) 4.49M
Net Income (ttm) -29.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -662.36%
Debt to Equity Ratio 0.00
Volume 14,571,800
Avg Vol 3,131,146
Day's Range N/A - N/A
Shares Out 26.01M
Stochastic %K 5%
Beta 0.94
Analysts Strong Sell
Price Target $7.00

Company Profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequatel...

Industry: Biotechnology
Sector: Healthcare
Phone: 609 495 2200
Website: palatin.com
Address:
11 Deer Park Drive, Suite 204, Monmouth Junction, United States
Rollercoaster22
Rollercoaster22 Aug. 18 at 6:12 PM
$PTN Very
0 · Reply
ajmrtxl
ajmrtxl Aug. 17 at 4:27 PM
$PTN 's latest data on SqueezeFinder
0 · Reply
Zephix
Zephix Aug. 13 at 9:33 PM
$MSGY $PTN T7
1 · Reply
kc444
kc444 Aug. 13 at 2:41 PM
$PTN sleeper!
0 · Reply
bbernier75
bbernier75 Aug. 13 at 2:40 PM
$PTN all that it will take is one influential person to notice this stick and it will tip
0 · Reply
bbernier75
bbernier75 Aug. 13 at 2:22 PM
$PTN
0 · Reply
Rollercoaster22
Rollercoaster22 Aug. 13 at 7:22 AM
$PTN Doesn't need much volume to move this. Just imagine what some good news could do. It would explode.
0 · Reply
bbernier75
bbernier75 Aug. 13 at 12:46 AM
$PTN #roaringkitty
0 · Reply
STACKD0E
STACKD0E Aug. 12 at 7:29 PM
$PTN 👀
0 · Reply
Rollercoaster22
Rollercoaster22 Aug. 12 at 6:33 PM
$PTN Bought more today at opening. A very good decision, indeed. 🤩
0 · Reply
Latest News on PTN
Palatin Technologies Slides: Corporate presentation

Aug 13, 2026, 8:00 AM EDT - 6 days ago

Palatin Technologies Slides: Corporate presentation

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Thu, 06 Aug 2026 09:40:00 -0400 - 12 days ago

StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It

Palatin Technologies Proxy statement: Proxy filing

Jun 25, 2026, 8:00 AM EDT - 7 weeks ago

Palatin Technologies Proxy statement: Proxy filing

Palatin Technologies Is Pursuing the Next Generation of MC4R. ...

2026-06-17T19:30:03.000Z - 2 months ago

Palatin Technologies Is Pursuing the Next Generation of MC4R. ...

Palatin Technologies Slides: Corporate presentation

May 29, 2026, 7:00 AM EDT - 2 months ago

Palatin Technologies Slides: Corporate presentation

Palatin announces approval of its common stock by Nasdaq

2026-05-18T20:08:48.000Z - 3 months ago

Palatin announces approval of its common stock by Nasdaq

Palatin to Begin Trading on Nasdaq Stock Exchange

Mon, 18 May 2026 16:00:00 -0400 - 3 months ago

Palatin to Begin Trading on Nasdaq Stock Exchange

Palatin price target lowered to $47.50 from $50 at Alliance Global

2026-05-14T17:24:55.000Z - 3 months ago

Palatin price target lowered to $47.50 from $50 at Alliance Global

Palatin Technologies Earnings Call Transcript: Q3 2026

May 13, 2026, 11:00 AM EDT - 3 months ago

Palatin Technologies Earnings Call Transcript: Q3 2026

Palatin Technologies Earnings release: Q3 2026

May 13, 2026, 11:00 AM EDT - 3 months ago

Palatin Technologies Earnings release: Q3 2026

Palatin Technologies Quarterly report: Q3 2026

May 13, 2026, 11:00 AM EDT - 3 months ago

Palatin Technologies Quarterly report: Q3 2026

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Wed, 13 May 2026 07:30:00 -0400 - 3 months ago

Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Palatin Technologies Slides: Corporate presentation

May 13, 2026, 7:00 AM EDT - 3 months ago

Palatin Technologies Slides: Corporate presentation

Palatin Technologies Slides: Corporate presentation

Mar 6, 2026, 6:00 AM EST - 5 months ago

Palatin Technologies Slides: Corporate presentation

Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline ...

2026-02-18T14:00:03.000Z - 6 months ago

Palatin Technologies' Rare-Obesity Strategy Sets Up a Catalyst-Rich 2026 for Its MC4R Pipeline ...

Palatin Technologies Earnings Call Transcript: Q2 2026

Feb 17, 2026, 11:00 AM EST - 6 months ago

Palatin Technologies Earnings Call Transcript: Q2 2026

Palatin Technologies Earnings release: Q2 2026

Feb 17, 2026, 11:00 AM EST - 6 months ago

Palatin Technologies Earnings release: Q2 2026

Palatin Technologies Quarterly report: Q2 2026

Feb 17, 2026, 11:00 AM EST - 6 months ago

Palatin Technologies Quarterly report: Q2 2026

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Tue, 17 Feb 2026 07:30:00 -0500 - 6 months ago

Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Technologies Slides: Corporate presentation

Feb 13, 2026, 7:00 AM EST - 6 months ago

Palatin Technologies Slides: Corporate presentation

Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN)

2026-01-12T15:30:03.000Z - 7 months ago

Palatin Technologies Targets Hypothalamic Obesity as Next Frontier Beyond GLP-1s (NYSE: PTN)

Palatin Technologies Inc trading resumes

2025-12-17T16:25:27.000Z - 8 months ago

Palatin Technologies Inc trading resumes

Palatin Technologies Inc trading halted, volatility trading pause

2025-12-17T16:20:21.000Z - 8 months ago

Palatin Technologies Inc trading halted, volatility trading pause

JANUS HENDERSON GROUP PLC Acquires Shares in Palatin Technologies Inc

2025-12-13T00:38:01.000Z - 8 months ago

JANUS HENDERSON GROUP PLC Acquires Shares in Palatin Technologies Inc

Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals

2025-12-12T10:05:19.000Z - 8 months ago

Palatin initiated with a Buy at LaidlawRhythm Pharmaceuticals

RYTM

Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?

2025-12-11T07:20:11.000Z - 8 months ago

Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?

Palatin initiated with a Buy at Alliance Global

2025-12-03T12:05:26.000Z - 9 months ago

Palatin initiated with a Buy at Alliance Global

Biotech Alert: Searches spiking for these stocks today

2025-11-24T15:30:17.000Z - 9 months ago

Biotech Alert: Searches spiking for these stocks today

SMMT

Palatin Technologies Inc trading resumes

2025-11-21T18:45:19.000Z - 9 months ago

Palatin Technologies Inc trading resumes

Palatin Technologies Inc trading halted, volatility trading pause

2025-11-21T18:35:17.000Z - 9 months ago

Palatin Technologies Inc trading halted, volatility trading pause

Palatin Technologies Inc trading resumes

2025-11-17T16:25:32.000Z - 9 months ago

Palatin Technologies Inc trading resumes

Palatin Technologies Inc trading halted, volatility trading pause

2025-11-17T16:20:31.000Z - 9 months ago

Palatin Technologies Inc trading halted, volatility trading pause

Palatin Technologies Inc trading resumes

2025-11-14T14:50:32.000Z - 9 months ago

Palatin Technologies Inc trading resumes

Palatin Technologies Inc trading halted, volatility trading pause

2025-11-14T14:41:20.000Z - 9 months ago

Palatin Technologies Inc trading halted, volatility trading pause

Palatin Technologies Earnings Call Transcript: Q1 2026

Nov 13, 2025, 11:00 AM EST - 9 months ago

Palatin Technologies Earnings Call Transcript: Q1 2026

Palatin Technologies Quarterly report: Q1 2026

Nov 13, 2025, 11:00 AM EST - 9 months ago

Palatin Technologies Quarterly report: Q1 2026

Palatin Technologies Earnings release: Q1 2026

Nov 13, 2025, 11:00 AM EST - 9 months ago

Palatin Technologies Earnings release: Q1 2026

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Thu, 13 Nov 2025 07:30:00 -0500 - 9 months ago

Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Nov 12, 2025, 12:15 PM EST - 9 months ago

Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

Palatin Technologies Registration statement: Registration Filing

Oct 17, 2025, 8:00 AM EDT - 10 months ago

Palatin Technologies Registration statement: Registration Filing

Palatin Technologies Registration statement: Registration Filing

Oct 1, 2025, 8:00 AM EDT - 11 months ago

Palatin Technologies Registration statement: Registration Filing

Palatin Technologies Registration statement: Registration Filing

Oct 1, 2025, 8:00 AM EDT - 11 months ago

Palatin Technologies Registration statement: Registration Filing

Palatin Technologies Annual report: Q4 2025

Sep 22, 2025, 6:00 PM EDT - 11 months ago

Palatin Technologies Annual report: Q4 2025

Palatin Technologies Proxy statement: Proxy Filing

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Proxy statement: Proxy Filing

Palatin Technologies Proxy statement: Proxy Filing

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Proxy statement: Proxy Filing

Palatin Technologies Earnings Call Transcript: Q3 2025

May 14, 2025, 11:00 AM EDT - 1 year ago

Palatin Technologies Earnings Call Transcript: Q3 2025

Palatin Technologies Quarterly report: Q3 2025

May 14, 2025, 11:00 AM EDT - 1 year ago

Palatin Technologies Quarterly report: Q3 2025

Palatin Technologies Earnings release: Q3 2025

May 14, 2025, 11:00 AM EDT - 1 year ago

Palatin Technologies Earnings release: Q3 2025

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

May 14, 2025, 7:30 AM EDT - 1 year ago

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update

PTNT

Two new option listings and two option delistings on May 9th

2025-05-09T12:36:35.000Z - 1 year ago

Two new option listings and two option delistings on May 9th

GOLD

Palatin presents preclinical data on PL9654 and PL9655 at ARVO

2025-05-09T11:36:25.000Z - 1 year ago

Palatin presents preclinical data on PL9654 and PL9655 at ARVO

Palatin presents results from Phase 3 PL9643 MELODY-1 trial

2025-05-08T20:50:06.000Z - 1 year ago

Palatin presents results from Phase 3 PL9643 MELODY-1 trial

Palatin announces transition to OTC Pink following NYSE American notice

2025-05-08T10:34:45.000Z - 1 year ago

Palatin announces transition to OTC Pink following NYSE American notice

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

May 7, 2025, 8:26 PM EDT - 1 year ago

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice

PTNT

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

May 7, 2025, 5:20 PM EDT - 1 year ago

NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)

Palatin trading halted, news pending

2025-05-07T16:30:16.000Z - 1 year ago

Palatin trading halted, news pending

Palatin expects $11.5M financing to cure NYSE American delisting notice

2025-05-07T12:23:20.000Z - 1 year ago

Palatin expects $11.5M financing to cure NYSE American delisting notice

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

May 7, 2025, 8:15 AM EDT - 1 year ago

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

May 7, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Announces Pricing of up to $23 Million Public Offering

Palatin Technologies Registration statement: Registration Filing

May 5, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Registration statement: Registration Filing

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

May 5, 2025, 7:30 AM EDT - 1 year ago

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Apr 17, 2025, 7:30 AM EDT - 1 year ago

Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide

Palatin Appeals NYSE American Notice of Delisting

Apr 14, 2025, 7:00 AM EDT - 1 year ago

Palatin Appeals NYSE American Notice of Delisting

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Apr 10, 2025, 4:01 PM EDT - 1 year ago

Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Apr 10, 2025, 7:30 AM EDT - 1 year ago

Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting

Palatin Technologies Registration statement: Registration Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Palatin Technologies Registration statement: Registration Filing

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Mar 31, 2025, 7:30 AM EDT - 1 year ago

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Mar 28, 2025, 7:30 AM EDT - 1 year ago

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Mar 25, 2025, 7:30 AM EDT - 1 year ago

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin Technologies Earnings Call Transcript: Q2 2025

Feb 13, 2025, 11:00 AM EST - 1 year ago

Palatin Technologies Earnings Call Transcript: Q2 2025

Palatin Technologies Earnings release: Q2 2025

Feb 13, 2025, 11:00 AM EST - 1 year ago

Palatin Technologies Earnings release: Q2 2025

Palatin Technologies Quarterly report: Q2 2025

Feb 13, 2025, 11:00 AM EST - 1 year ago

Palatin Technologies Quarterly report: Q2 2025

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Feb 13, 2025, 7:30 AM EST - 1 year ago

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Feb 10, 2025, 4:00 PM EST - 1 year ago

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Feb 7, 2025, 8:00 AM EST - 1 year ago

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Feb 6, 2025, 7:30 AM EST - 1 year ago

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Jan 28, 2025, 7:30 AM EST - 1 year ago

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Dec 19, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

Dec 16, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds

PTN

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

Nov 25, 2024, 7:30 AM EST - 1 year ago

Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

PTN

Palatin Technologies Earnings Call Transcript: Q1 2025

Nov 14, 2024, 11:00 AM EST - 1 year ago

Palatin Technologies Earnings Call Transcript: Q1 2025

Palatin Technologies Quarterly report: Q1 2025

Nov 14, 2024, 11:00 AM EST - 1 year ago

Palatin Technologies Quarterly report: Q1 2025

Palatin Technologies Earnings release: Q1 2025

Nov 14, 2024, 11:00 AM EST - 1 year ago

Palatin Technologies Earnings release: Q1 2025

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Nov 14, 2024, 7:30 AM EST - 1 year ago

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

PTN

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

Nov 8, 2024, 9:57 AM EST - 1 year ago

Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024

PTN

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

Nov 4, 2024, 7:30 AM EST - 1 year ago

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024

PTN

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

PTN

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

Oct 24, 2024, 7:30 AM EDT - 1 year ago

Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium

PTN

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium

PTN

Palatin Technologies Registration statement: Registration Filing

Oct 22, 2024, 8:00 AM EDT - 1 year ago

Palatin Technologies Registration statement: Registration Filing

Palatin Receives Notice of Non-Compliance from NYSE American

Oct 7, 2024, 4:15 PM EDT - 2 years ago

Palatin Receives Notice of Non-Compliance from NYSE American

PTN

Palatin Technologies Earnings Call Transcript: Q4 2024

Oct 1, 2024, 11:00 AM EDT - 2 years ago

Palatin Technologies Earnings Call Transcript: Q4 2024

Palatin Technologies Earnings release: Q4 2024

Oct 1, 2024, 11:00 AM EDT - 2 years ago

Palatin Technologies Earnings release: Q4 2024

Palatin Technologies Annual report: Q4 2024

Oct 1, 2024, 11:00 AM EDT - 2 years ago

Palatin Technologies Annual report: Q4 2024

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Oct 1, 2024, 7:30 AM EDT - 2 years ago

Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

PTN

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

Sep 26, 2024, 7:30 AM EDT - 2 years ago

Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results

PTN

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

Sep 9, 2024, 7:30 AM EDT - 2 years ago

Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones

PTN

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Aug 28, 2024, 7:30 AM EDT - 2 years ago

FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

PTN

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Aug 22, 2024, 7:30 AM EDT - 2 years ago

First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

PTN

Palatin Technologies Registration statement: Registration Filing

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Palatin Technologies Registration statement: Registration Filing

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

Jun 21, 2024, 8:00 AM EDT - 2 years ago

Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds

PTN

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

Jun 20, 2024, 7:30 AM EDT - 2 years ago

Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)

PTN

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Jun 12, 2024, 7:30 AM EDT - 2 years ago

Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

PTN

Palatin Technologies Proxy statement: Proxy Filing

May 28, 2024, 8:00 AM EDT - 2 years ago

Palatin Technologies Proxy statement: Proxy Filing

Palatin Technologies Earnings Call Transcript: Q3 2024

May 15, 2024, 11:00 AM EDT - 2 years ago

Palatin Technologies Earnings Call Transcript: Q3 2024

Palatin Technologies Quarterly report: Q3 2024

May 15, 2024, 11:00 AM EDT - 2 years ago

Palatin Technologies Quarterly report: Q3 2024

Palatin Technologies Earnings release: Q3 2024

May 15, 2024, 11:00 AM EDT - 2 years ago

Palatin Technologies Earnings release: Q3 2024

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

May 15, 2024, 7:30 AM EDT - 2 years ago

Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

PTN

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

May 9, 2024, 7:30 AM EDT - 2 years ago

Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024

PTN

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

May 2, 2024, 7:30 AM EDT - 2 years ago

Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity

PTN

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024

PTN

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

Apr 8, 2024, 7:30 AM EDT - 2 years ago

Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024

PTN

Palatin Technologies Registration statement: Registration Filing

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Palatin Technologies Registration statement: Registration Filing

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Feb 28, 2024, 7:30 AM EST - 2 years ago

Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

PTN

Palatin Technologies Earnings Call Transcript: Q2 2024

Feb 15, 2024, 11:00 AM EST - 2 years ago

Palatin Technologies Earnings Call Transcript: Q2 2024

Palatin Technologies Quarterly report: Q2 2024

Feb 15, 2024, 11:00 AM EST - 2 years ago

Palatin Technologies Quarterly report: Q2 2024

Palatin Technologies Earnings release: Q2 2024

Feb 15, 2024, 11:00 AM EST - 2 years ago

Palatin Technologies Earnings release: Q2 2024

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

Feb 15, 2024, 7:30 AM EST - 2 years ago

Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update

PTN

Rollercoaster22
Rollercoaster22 Aug. 18 at 6:12 PM
$PTN Very
0 · Reply
ajmrtxl
ajmrtxl Aug. 17 at 4:27 PM
$PTN 's latest data on SqueezeFinder
0 · Reply
Zephix
Zephix Aug. 13 at 9:33 PM
$MSGY $PTN T7
1 · Reply
kc444
kc444 Aug. 13 at 2:41 PM
$PTN sleeper!
0 · Reply
bbernier75
bbernier75 Aug. 13 at 2:40 PM
$PTN all that it will take is one influential person to notice this stick and it will tip
0 · Reply
bbernier75
bbernier75 Aug. 13 at 2:22 PM
$PTN
0 · Reply
Rollercoaster22
Rollercoaster22 Aug. 13 at 7:22 AM
$PTN Doesn't need much volume to move this. Just imagine what some good news could do. It would explode.
0 · Reply
bbernier75
bbernier75 Aug. 13 at 12:46 AM
$PTN #roaringkitty
0 · Reply
STACKD0E
STACKD0E Aug. 12 at 7:29 PM
$PTN 👀
0 · Reply
Rollercoaster22
Rollercoaster22 Aug. 12 at 6:33 PM
$PTN Bought more today at opening. A very good decision, indeed. 🤩
0 · Reply
OutraguesTax
OutraguesTax Aug. 12 at 6:26 PM
$PTN any news????
0 · Reply
MauriceMauriceMaurice
MauriceMauriceMaurice Aug. 8 at 9:38 PM
$PTN jorking it
0 · Reply
focafoca99
focafoca99 Aug. 6 at 1:50 PM
$PTN anticipates IND submissions for next-gen MC4R candidates in Q4 2026 and H1 2027. https://www.rapidticker.com/news/ptn-streetwatch-a-29-billion-takeover-687bea
0 · Reply
newsfile_corp
newsfile_corp Aug. 6 at 1:41 PM
https://nfne.ws/308315 $PTN #Publishing #NASDAQ #Investing
0 · Reply
Tpharma
Tpharma Aug. 5 at 2:26 PM
$PTN How’s this stock doing? I see they got listed again. The debacle that saw them get knocked off the exchange previously, then they did reverse split to get back on. Now burning through cash again. Any clinical milestones due to be reached soon? Although it doesnt mean anything, last time they had positive P2 results in three trials their share price went down 75%.
1 · Reply
SportTrade
SportTrade Aug. 5 at 10:13 AM
$PTN see results from RYTM showing evidence that once-weekly formulation targeting MC4R agonist for HO works! I view that as massively derisking for PTN. Stock down 60% since last earnings bc of delay in filing IND that is preposterous. Thesis remains they file IND in Q4 and start trial 30days after (warrant infusion kicks in after IND cleared) and we get Ph1 results with HO oatients to see an efficacy signal. RYTm has an enterprise value of $6.7Billion vs PTN trading nearly at cash value with EV of $5M… hello… there is upside ahead if they execute!!! https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-reports-second-quarter-2026-financial https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-preliminary-data-phase-2-trial
0 · Reply
ajmrtxl
ajmrtxl Aug. 3 at 5:36 PM
$PTN 's latest squeeze play
0 · Reply
Stocks787
Stocks787 Aug. 3 at 11:13 AM
$PTN 😞😞😞😞😞💩
0 · Reply
DarkWatcher
DarkWatcher Jul. 30 at 3:12 PM
$PTN are you buying a ticket for the ride?
0 · Reply
Rollercoaster22
Rollercoaster22 Jul. 30 at 10:42 AM
$PTN Still
0 · Reply
WallStWireAds
WallStWireAds Jul. 29 at 2:24 PM
$PTN
0 · Reply
kc444
kc444 Jul. 29 at 2:21 PM
$PTN The price moves in this stock reeks of manipulation. Given their drug pipeline there is no reason to be selling at this price. They need to get to at least Phase 3 and much better promotion. If they could reach Phase 3 on any of their drugs it would be a huge win. They have GLP1, UC, Diabetics neuropathy, and Dry eye disease meds, all sitting at Phase 2 for way too long. I invested because I believe these medications could help a lot of people, hopefully they can actually deliver.
0 · Reply